Virus filtration

PDA Journal of Pharmaceutical Science and Technology

Volumn 62, Issue SUPPL. 4, 2008, Pages 1-60

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADSORPTION; ANALYTIC METHOD; ARTICLE; AUTOCLAVE; BACTERIOPHAGE; BIOCOMPATIBILITY; BIOPROCESS; DRUG MANUFACTURE; FILTRATION; GAS FLOW; GAS STERILIZATION; GOOD LABORATORY PRACTICE; HEAT TOLERANCE; INDUSTRIAL HYGIENE; INSTRUMENT STERILIZATION; MEMBRANE FILTER; MEMBRANE PERMEABILITY; METHODOLOGY; PARTICLE SIZE; POROSITY; PRESSURE; PRESSURE DECAY TEST; PROTEIN AGGREGATION; RADIATION STERILIZATION; STORAGE; ULTRAFILTRATION; VALIDATION PROCESS; VIRUS FILTER; VIRUS FILTRATION; VIRUS PARTICLE; VIRUS STOCK PREPARATION;

EID: 57749116130     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Chamberland, M. E. Emerging Infectious Agents: Do They Pose a Risk to the Safety of Transfused Blood and Blood Products? Clin. Infect. Dis. 2002, 34, 797-805.
2. Farrugia, A. Evolving Perspectives in Product Safety for Haemophilia. Haemophilia. 2002, 8, 236-243.
3. Farshid, M.; Taffs, R. E.; Scott, D.; Asher D. M.; Brorson, K. The Clearance of Viruses and Transmissible Spongiform Encephalopathy Agents from Biologicals. Curr. Opin. Biotechnol. 2005, 16, 561-567.
4. Garnick, R. L. Experience with Viral Contamination in Cell Culture. Dev. Biol. Stand. 1996, 88, 49-56.
5. Garnick, R. L. Raw Materials as a Source of Contamination in Large-Scale Cell Culture. Dev. Biol. Stand. 1998, 93, 21-29.
6. Lieber, M. M.; Benveniste, R. E.; Livingston, D. M.; Todaro, G. J.; Mammalian Cells in Culture Frequently Release Type C Viruses. Science. 1973, 182(107), 56-59.
7. Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses (CPMP/BWP/268/95). European Medicines Agency: 1995.
8. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. U.S. Food and Drug Administration: 1997.
9. Quality Guideline Q5A: Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin. International Conference on Harmonisation: 1997.
10. Brorson, K.; Swann, P. G.; Brown, J.; Wilcox, B.; Shapiro, M.; Considerations for Developing Biopharmaceuticals: FDA Perspective. In Modern Biopharmaceuticals Design, Development and Optimization; Knablein, J., Ed.; WILEY-VCH Verlag GmbH & Co, KGaA: Weinheim, Germany, 2005; Vol. 4, pp 1637-1668.
11. Aranha, H.; Viral Clearance Strategies for Biopharmaceutical Safety. Part 1: General Considerations. Biopharm Intl. 2001, 14(2), 28-35.
12. Aranha, H.; Viral Clearance Strategies for Biopharmaceutical Safety. Part 2: Filtration for Viral Clearance. Biopharm Intl. 2001, 14(2), 32-43.
13. Aranha-Creado, H.; Oshima, K.; Jafari, S.; Howard, G. Jr.; Brandwein, H. Virus Retention by a Hydrophilic Triple-layer PVDF Microporous Membrane Filter. PDA J Pharm. Sci. Technol. 1997, 51, 119-124.
14. Burnouf-Radosevich, M.; Appourchaux, P.; Huart, J. J.; Burnouf, T. Nanofiltration, A New Specific Virus Elimination Method Applied to High-purity Factor IX and Factor XI Concentrates. Vox Sang. 1994, 67, 132-138.
15. DiLeo, A.J.; Vacante, D. A.; Deane, E. F. Size Exclusion Removal of Model Mammalian Viruses Using a Unique Membrane System, Part II: Module Qualification and Process Simulation. Biologicals. 1993, 21, 287-296.
16. DiLeo, A. J.; Vacante, D. A.; Deane, E. F. Size Exclusion Removal of Model Mammalian Viruses Using a Unique Membrane System, Part I: Membrane Qualification. Biologicals. 1993, 21, 275-286.
17. Hoffer, L.; Schwinn, H.; Biesert, L.; Josic, D. Improved Virus Safety and Purity of a Chromatographically Produced Factor IX Concentrate by Nanofiltration. J. Chromatogr. B: Biomed. Sci. Appl. 1995, 669, 187-196.
18. Levy R.; Philips, M.; Lutz, H. Filtration and Removal of Viruses from Biopharmaceuticals. In Filtration in the Biopharmaceutical Industry; Meltzer, T.; Jornitz, M., Eds.; Marcel Dekker, Inc.: New York. 1998; pp 619-646.
19. Manabe, S. Removal of Virus Through Novel Membrane Filtration Method. Dev. Biol. Stand. 1996, 88, 81-90.
20. O'Grady, J.; Losikoff, A.; Poiley, J.; Fickett, D.; Oliver, C. Virus Removal Studies Using Nanofiltration Membranes. In Viral Safety and Evaluation of Viral Clearance from Biopharmaceutical Products; Brown, F.; Lubiniecki, A., Eds.; Karger: Basel, Switzerland, 1996; pp 319-326.
21. Troccoli, N. M.; McIver, J.; Losikoff, A.; Poiley, J. Removal of Viruses from Human Intravenous Immune Globulin by 35 nm Nanofiltration. Biologicals. 1998, 26, 321-329.
22. Grant, D. C.; Liu, B. Y. H.; Fischer, W. G.; Bowling, R. A. Particle Capture Mechanisms in Gases and Liquids: An Analysis of Operative Mechanisms. J. Environ. Sci. 1989, 42 (4), pp 43-51.
23. Lute, S.; Bailey M.; Combs, J.; Sukumar, M.; Brorson, K. Phage Passage after Extended Processing in Small-Virus-Retentive Filters. Biotechnol. Appl. Biochem. 2007, 47 (Pt 3), 141-151.
24. Brough, H.; Antoniou, C.; Carter, J.; Jakubik, J.; Xu, Y.; Lutz, H. Performance of a Novel Viresolve NFR Virus Filter. Biotechnol. Prog. 2002, 18, 782-795.
25. Bolton, G.; Cabatingan, M.; Rubino, M.; Lute, S.; Brorson, K.; Bailey M. Normal-Flow Virus Filtration: Detection and Assessment of the Endpoint in Bio-Processing. Biotechnol. Appl. Biochem. 2005, 42 (Pt 2), 133-142.
26. Hirasaki, T.; Nakano, H.; Ishizaki, Y.; Manabe, S.; Yamamoto, N. Mechanism of Removing Japanese Encephalitis Virus (Lev) and Gold Particles using Cuprammonium Regenerated Cellulose Hollow Fiber (I-BMM Or BMM) from Aqueous Solution Containing Protein. Polym. J. 1994, 26, 1244-1256.
27. Bradley D. The Structure and Infective Process of a Pseudomonas Aeruginosa Bacteriophage containing Ribonucleic Acid. J. Gen. Microbiol. 1966, 45, 83-96.
28. Coetzee,J. N.; Lecatsas, G.; Coetzee, W. F.; Hedges, R. W. Properties of R Plasmid R772 and the Corresponding Pilus-specific Phage PR772. J. Gen. Microbiol. 1979, 110, 263-273.
29. Coetzee, W. F.; Bekker, P. J. Pilus-specific, Lipid-containing Bacteriophages PR4 and PR772: Comparison of Physical Characteristics of Genomes. J. Gen. Virol. 1979, 45, 195-200.
30. Olsthoorn, R. C.; Garde, G.; Dayhuff, T.; Atkins, J. F.; Van Duin, J. Nucleotide Sequence of a Single-stranded RNA Phage from Pseudomonas Aeruginosa: Kinship to Coliphages and Conservation of Regulatory RNA Structures. Virology. 1995, 206, 611-625.
31. Lute, S.; Aranha, H.; Tremblay, D.; Liang, D.; Ackermann, H. W.; Chu, B.; Moineau, S.; Brorson, K. Characterization of Coliphage PR772 and Evaluation of its use for Virus Filter Performance Testing. Appl. Environ. Microbiol. 2004, 70, 4864-4871.
32. Brorson, K.; Lute, S.; Haque, M.; Sato, T.; Moroe, I.; Morgan, M.; Krishnan, M.; Campbell J.; Genest, P.; Parrella, J.; Dolan, S.; Martin, S. A Consensus Rating Method for Small Virus Retentive Filters. II, Method Evaluation. PDA J. Pharm. Sci. Technol. 2008, 62, 334-343.
33. Brorson, K.; Sofer, G.; Aranha, H.; Nomenclature Standardization for 'Large Pore Size' Virus-Retentive Filters. PDA J. Pharm. Sci. Technol. 2005, 59, 341-345.
34. Brorson, K.; Sofer, G.; Robertson, G.; Lute, S.; Martin, J.; Aranha, H.; Haque, M.; Satoh, S. Yoshinari, K.; Moroe, I.; et.al. "Large Pore Size" Virus Filter Test Method Recommended by the PDA Virus Filter Task Force. PDA J Pharm. Sci. Technol. 2005, 59, 177-186.
35. Pujar, N. S.; Zydney A. L. Electrostatic Effects on Protein Partitioning in Size-Exclusion Chromatography and Membrane Ultrafiltration. J. Chromatogr. A. 1998 796, 229-238.
36. Technical Report No. 26: Sterilizing Filtration of Liquids; Parenteral Drug Association: Bethesda, MD, 1998.
37. Carter, J.; Lutz, H. Validation of Virus Filtration: Ensuring Regulatory Compliance. BioPro. Intl. 2003, 1(1), 52-62.
38. Lute, S.; Riordan, W.; Pease, L.; Tsai, D.; Levy R.; Haque, M.; Moroe, I.; Sato, T.; Morgan, M.; Krishnan, M.; et al. A Consensus Rating Method for Small Virus Retentive Filters. I. Method Development. PDA J. Pharm. Sci. Technol. 2008, 62, 318-333.
39. Oshima, K. H.; Evans-Strickfaden, T.; Highsmith, A. Comparison of Filtration Properties of Hepatitis B Virus, Hepatitis C Virus and Simian Virus 40 Using a Polyvinylidene Fluoride Membrane Filter. Vox Sang. 1998, 75, 181-188.
40. Oshima, K. H.; Evans-Strickfaden, T.; Highsmith, A.; Ades, E. The Use of a Microporous Polyvinylidene Fluoride (PVDF) Membrane Filter to Separate Contaminating Viral Particles from Biologically Important Proteins. Biologicals. 1996, 24, 137-145.
41. Earnshaw, W. C.; King, J.; Eiserling, F. A. The Size Of The Bacteriophage T4 Head in Solution with Comments about the Dimension of Virus Particles as Visualized by Electron Microscopy. J. Mol. Biol. 1978, 122, 247-253.
42. Korneyeva, M.; Charles, P.; Li, H.; McNaull, S.; Smith, S.; Petteway S.; Pifat, D. Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma Derived Protein with Thrombolytic Activity. Int. J. Hematol. 2002, 76 (Sup. 1), 29.
43. Xu, Y.; Brorson, K. An Overview Of Quantitative PCR Assays For Biologicals: Quality And Safety Evaluation. Dev. Biol. 2003, 113, 89-98.
44. Quality Guideline Q2(R1): Validation of Analytical Procedures: Text and Methodology; International Conference on Harmonisation: 2005.
45. Quality Guideline Q8: Pharmaceutical Development; International Conference on Harmonisation: 2005.